Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Rizcallah Dick"'
Autor:
Rizcallah Dick, Maria Octavia Rangel, Rami Doukky, Sarah T. Voll, Raysa Morales Demori, Marwan Wassouf
Publikováno v:
Journal of Nuclear Cardiology. 22:1008-1018
Regadenoson is predominantly renally metabolized. Patients with severe chronic kidney disease (CKD) experience more frequent gastrointestinal adverse effects (AE) from regadenoson. Aminophylline use following regadenoson reduces the incidence of rega
Autor:
Ammar Alqaid, Bosko Margeta, Rizcallah Dick, Maria Octavia Rangel, Rami Doukky, Marwan Wassouf
Publikováno v:
The international journal of cardiovascular imaging. 29(5)
A subgroup analysis of the ASSUAGE trial suggested that the standardized intravenous aminophylline administration following regadenoson-stress leads to substantial attenuation of regadenoson adverse-effects in patients with severe chronic kidney dise
Autor:
Ammar Alqaid, Marwan Wassouf, Rizcallah Dick, Maria Octavia Rangel, Rami Doukky, Raysa Morales Demori
Publikováno v:
Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology. 20(2)
There has not been any prospective evaluation of the safety and tolerability of regadenoson (REG)-stress in patients with end-stage renal disease (ESRD).From the pooled database of two identically designed randomized, double-blinded, placebo-controll
Autor:
Maria Octavia Rangel, Rojina Pant, Rami Doukky, Raysa Morales-Demori, Rizcallah Dick, Marwan Wassouf, Bosko Margeta
Publikováno v:
Journal of the American College of Cardiology. 59:E1313
Regadenoson (REG) appears to be safe in patients with end-stage renal disease (ESRD) on the basis of two retrospective studies. A prospective, placebo-controlled clinical trial by Palani et al found REG to be safe in chronic kidney disease (CKD) stag
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.